杰诺维DPP-4抑制剂同及异.pptVIP

we selected 90 type 2 diabetic patients (43 men and 47 women) without adequate glycemic control (HbA1c.7.5%) on metformin treatment at maximal dose (2,000 mg/day) for at least 8 weeks before enrollment. A prospective, randomized, open-label PROBE design (parallel group with a blinded end point) study was performed. The study assigned 45 patients to receive sitagliptin (100 mg once daily; sitagliptin group) and 45 patients to receive vildagliptin(50 mg twice daily; vildagliptin group) for 12 weeks.HbA1c baseline 8.5% * * 糖尿病患者的肝肾功能是治疗中经常被考虑的问题，捷诺维在肾功能不全的患者进行剂量调整，就可以安全使用。在轻、中度肝功能不全的患者，也可以使用。 沙格列汀不推荐在中、重度肾功能、重度肝功能不全患者的使用，在中度肝功能不全患者中，无需调整剂量但需谨慎使用。 维沙格列汀不被推荐在中、重度肾功能，轻、中、重度肝功能不全患者中处方。 We included studies in this meta-analysis if (1) they were RCTs comparing DPP4 inhibitor monotherapy in 1 arm to other oral antitype 2 DM agents (other than DPP4 inhibitors) in the comparator arm, (2) duration of treatment was 24 weeks, and (3) reported data on adverse CV side effects of DPP4 inhibitor therapy (death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke, heart failure, and arrhythmias).The quality of included articles was further assessed。 The primary end point was development of adverse CV events defined as death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke and arrhythmias (including atrial fibrillation, supraventricular tachycardia, or palpitations), and heart failure. * We included studies in this meta-analysis if (1) they were RCTs comparing DPP4 inhibitor monotherapy in 1 arm to other oral antitype 2 DM agents (other than DPP4 inhibitors) in the comparator arm, (2) duration of treatment was 24 weeks, and (3) reported data on adverse CV side effects of DPP4 inhibitor therapy (death from CV causes, nonfatal myocardial infarction or acute coronary syndrome, stroke, heart failure, and arrhythmias).The quality of included articles was further assessed。 The primary end point was development of adverse CV event